Home › Trial NCT01446159
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
- Trial IDNCT01446159
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorMedImmune LLC
- Enrollment188
- Start date2011-06-13
- ConditionsHormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.